New Review of Neurorehabilitation in Multiple Sclerosis - Resilience in Practice

LONDON, September 19, 2017 /PRNewswire/ --

Jürg Kesselring, European Neurological Review, 2017;12(1):31-6 DOI: https://doi.org/10.17925/ENR.2017.12.01.31

     (Logo: http://mma.prnewswire.com/media/515766/Touch_Medical_Logo.jpg )

Published recently in European Neurological Review the peer-reviewed journal from touchNEUROLOGY, Professor Kesselring stresses that although enormous strides have been made in the efficacy and range of disease-modifying drugs for the treatment of multiple sclerosis (MS) there is another equally important concept that is neurorehabilitation. , Key factors that contribute to the impact of neurorehabilitation include resilience and neuroplasticity. In the former, components such as nutrition, self-belief and physical activity provide a stronger response to the disease and improved responses to treatment. Neuroplasticity is the capacity of the brain to establish new neuronal networks after lesion damage has occurred and distant brain regions assume control of lost functions. In MS, it is vital that each patient is treated by a coordinated multidisciplinary team. This enables all aspects of the disease including problems with mobility, gait, bladder/bowel disturbances, fatigue and depression to be effectively treated. It is also important that the treating team adopts current best practice and provides internationally agreed standards of care. A further vital aspect of MS management is patient engagement, in which individuals are fully involved and are encouraged to strive and put effort into meeting treatment goals. In this approach, healthcare providers become motivators and patients need less intervention and consume fewer resources. Numerous interventions that promote neurorehabilitation are available, though evidence to support their use is limited by a lack of data from large randomised controlled trials. Overall Professor Kesselring emphasises that combining interventions that promote neurorehabilitation with newer, more effective treatments creates a promising potential to substantially improve the outlook for patients at all stages of MS.

The full peer-reviewed, open-access article is available here:

https://doi.org/10.17925/ENR.2017.12.01.31

Disclosure: Jürg Kesselring has nothing to disclose in relation to this article. No support was received for the publication of this article.

touchNEUROLOGY (a division of Touch Medical Media) publishes European Neurological Review, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of neurology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.

www.touchNEUROLOGY.com

"Touch Medical Media is a trading name of Touch Digital Media Limited, a private limited company registered in England and Wales at The White House Mill Road, Goring, Reading, England, RG8 9DD with registered number 08197142".

For inquires please contact:
Christina Mackins
Crabtree, PhD, CMPP - Managing Editor
[email protected]

"Leading the Debate on the Advances in Healthcare"

SOURCE touchNEUROLOGY